- Home
- BGNE vs BAM Comparison
BGNE vs BAM Comparison
Compare BGNE & BAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGNE
- BAM
- Stock Information
- Founded
- BGNE 2010
- BAM 2022
- Country
- BGNE Cayman Islands
- BAM Canada
- Employees
- BGNE N/A
- BAM N/A
- Industry
- BGNE Biotechnology: Pharmaceutical Preparations
- BAM
- Sector
- BGNE Health Care
- BAM
- Exchange
- BGNE Nasdaq
- BAM Nasdaq
- Market Cap
- BGNE 21.0B
- BAM 19.8B
- IPO Year
- BGNE 2016
- BAM N/A
- Fundamental
- Price
- BGNE $189.23
- BAM $55.73
- Analyst Decision
- BGNE Buy
- BAM Buy
- Analyst Count
- BGNE 7
- BAM 13
- Target Price
- BGNE $247.07
- BAM $51.38
- AVG Volume (30 Days)
- BGNE 281.8K
- BAM 1.2M
- Earning Date
- BGNE 11-12-2024
- BAM 11-04-2024
- Dividend Yield
- BGNE N/A
- BAM 2.73%
- EPS Growth
- BGNE N/A
- BAM N/A
- EPS
- BGNE N/A
- BAM 1.09
- Revenue
- BGNE $3,351,304,621.00
- BAM N/A
- Revenue This Year
- BGNE $969.39
- BAM N/A
- Revenue Next Year
- BGNE $24.79
- BAM $18.47
- P/E Ratio
- BGNE N/A
- BAM $52.27
- Revenue Growth
- BGNE 50.22
- BAM N/A
- 52 Week Low
- BGNE $126.97
- BAM $33.06
- 52 Week High
- BGNE $248.16
- BAM $58.53
- Technical
- Relative Strength Index (RSI)
- BGNE 31.72
- BAM 63.50
- Support Level
- BGNE $189.60
- BAM $55.59
- Resistance Level
- BGNE $209.29
- BAM $58.53
- Average True Range (ATR)
- BGNE 6.42
- BAM 1.45
- MACD
- BGNE -2.10
- BAM -0.12
- Stochastic Oscillator
- BGNE 9.19
- BAM 55.13
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
About BAM Brookfield Asset Management Inc Limited Voting Shares
Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.